TY - JOUR
T1 - Effects of conditioned medium obtained from human adipose-derived stem cells on skin inflammation
AU - Yano, Fumiko
AU - Takeda, Taiga
AU - Kurokawa, Takafumi
AU - Tsubaki, Toshiya
AU - Chijimatsu, Ryota
AU - Inoue, Keita
AU - Tsuji, Shinsaku
AU - Tanaka, Sakae
AU - Saito, Taku
N1 - Funding Information:
We thank J. Sugita, D. Mori, and R. Homma for providing technical assistance. We thank Emma Longworth-Mills, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript. This work was performed as collaborative research among the CPC Corporation, Kyowa Co. Ltd. and the University of Tokyo.
Publisher Copyright:
© 2022 The Japanese Society for Regenerative Medicine
PY - 2022/6
Y1 - 2022/6
N2 - Introduction: Cell therapy using adipose-derived mesenchymal stem cells (ASCs) is a promising avenue of regenerative medicine for the treatment of various diseases. It has been considered that ASCs exert their therapeutic effects through the secretion of multiple factors that are critical for tissue remodeling or the suppression of inflammation. Recently, conditioned medium (CM) from ASCs that contains a complex of secreted factors has received attention as a cost-effective alternative to cell therapy. Methods: We investigated the effects of CM obtained from ASCs (ASCs-CM) using human dermal fibroblasts (hDFs) and human epidermal keratinocytes with or without interleukin (IL)-1β and examined mRNA levels of marker genes. We also examined alterations in cell proliferation and morphology of hDFs following treatment with ASCs-CM. We further investigated the effects of ASCs-CM treatment on prevention of skin inflammation using a mouse model. Results: In hDFs and human epidermal keratinocytes, the ASCs-CM treatment suppressed pro-inflammatory factors and enhanced regenerative and remodeling factors with or without interleukin (IL)-1β exposure. The ASCs-CM treatment also enhanced cell proliferation of hDFs and prevented morphological changes in response to IL-1β exposure. Furthermore, in a mouse model of skin inflammation, treatment with ASCs-CM reduced the inflammatory reactions, including redness and thickness. Conclusions: CM from ASCs may represent a potential alternative to ASC therapy for the treatment of inflammatory skin conditions.
AB - Introduction: Cell therapy using adipose-derived mesenchymal stem cells (ASCs) is a promising avenue of regenerative medicine for the treatment of various diseases. It has been considered that ASCs exert their therapeutic effects through the secretion of multiple factors that are critical for tissue remodeling or the suppression of inflammation. Recently, conditioned medium (CM) from ASCs that contains a complex of secreted factors has received attention as a cost-effective alternative to cell therapy. Methods: We investigated the effects of CM obtained from ASCs (ASCs-CM) using human dermal fibroblasts (hDFs) and human epidermal keratinocytes with or without interleukin (IL)-1β and examined mRNA levels of marker genes. We also examined alterations in cell proliferation and morphology of hDFs following treatment with ASCs-CM. We further investigated the effects of ASCs-CM treatment on prevention of skin inflammation using a mouse model. Results: In hDFs and human epidermal keratinocytes, the ASCs-CM treatment suppressed pro-inflammatory factors and enhanced regenerative and remodeling factors with or without interleukin (IL)-1β exposure. The ASCs-CM treatment also enhanced cell proliferation of hDFs and prevented morphological changes in response to IL-1β exposure. Furthermore, in a mouse model of skin inflammation, treatment with ASCs-CM reduced the inflammatory reactions, including redness and thickness. Conclusions: CM from ASCs may represent a potential alternative to ASC therapy for the treatment of inflammatory skin conditions.
KW - Adipose-derived mesenchymal stem cells (ASCs)
KW - ASC therapy
KW - Conditioned medium (CM)
KW - Human dermal fibroblasts (hDFs)
KW - Interleukin (IL)-1β
KW - Skin inflammation
UR - http://www.scopus.com/inward/record.url?scp=85128173681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128173681&partnerID=8YFLogxK
U2 - 10.1016/j.reth.2022.03.009
DO - 10.1016/j.reth.2022.03.009
M3 - Article
AN - SCOPUS:85128173681
SN - 2352-3204
VL - 20
SP - 72
EP - 77
JO - Regenerative Therapy
JF - Regenerative Therapy
ER -
